Transplant News and Research

RSS

Obeticholic acid meets primary composite endpoint in Phase III study

Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC.

15 Apr 2014

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute.

15 Apr 2014

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.

11 Apr 2014

New research provides new hope for liver transplant patients with recurring hepatitis C

New research announced at the International Liver CongressTM 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).

11 Apr 2014

Study shows impact of hepatic encephalopathy on liver disease patients

New data presented today at the International Liver Congress show the impact of hepatic encephalopathy on liver disease patients and healthcare systems.

11 Apr 2014

Inserm plays key role in developing European research

The French National Institute of Health and Medical Research (Inserm) is currently the leading biomedical research organisation in Europe, and plays a key role in developing European research. To mark its 50th anniversary, Inserm wanted to assess the perceptions of Europeans regarding biomedical research.

10 Apr 2014

Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

In the UK paracetamol toxicity is the most common cause of ALF and has a high mortality rate. It is estimated that 150 to 200 deaths and 15 to 20 LTs occur as a result of poisoning each year in England and Wales.

10 Apr 2014

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from two Phase 2 studies evaluating investigational all-oral regimens containing the nucleotide analog polymerase inhibitor sofosbuvir (SOF) for the treatment of chronic hepatitis C virus (HCV) infection.

10 Apr 2014

Restoration Robotics presents revolutionary robotic systems at Orlando Live Surgery Workshop

Restoration Robotics, Inc., the global leader in robotic hair transplantation, will have Craig Ziering, DO, present ARTAS Hair Studio™ and the ARTAS® Robotic System during the Platinum Orlando Live Surgery Workshop taking place April 9 through 12 in Orlando, FL.

9 Apr 2014

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the QUANTUM-R Phase 3 clinical trial comparing quizartinib as monotherapy to chemotherapy regimens in relapsed/refractory acute myeloid leukemia (AML) patients with the FMS-like tyrosine kinase-3 (FLT3)-ITD mutation.

8 Apr 2014

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients

Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.

From Santen Pharmaceutical Co., Ltd. 7 Apr 2014

MCVI receives federal approval to launch adult heart transplant program at Memorial Regional Hospital

The Memorial Cardiac and Vascular Institute (MCVI), a leading provider of adult cardiac services in South Florida, has received federal approval from UNOS (United Network for Organ Sharing) to launch an adult heart transplant program at Memorial Regional Hospital in Hollywood.

4 Apr 2014

Transplant drugs may help defeat HIV

Drugs that are currently given to prevent organ rejection in patients who have received a transplant may offer a new approach to curing HIV, say researchers.

3 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

Research findings suggest new strategy in fight against HIV infection

New research suggests that drugs commonly used to prevent organ rejection after transplantation may also be helpful for combating HIV. The findings, which are published in the American Journal of Transplantation, suggest a new strategy in the fight against HIV and AIDS.

3 Apr 2014

Researcher finds simple blood test that predicts person's risk for sudden cardiac death

A researcher at the Cardiovascular Institute (CVI) at Rhode Island, The Miriam and Newport hospitals has found that a simple blood test can predict a person's risk for sudden cardiac death, enabling physicians to more quickly and accurately assess a patient's need for an implantable cardiac defibrillator (ICD).

3 Apr 2014

AB Sciex launches immunosuppressants kit to improve health care

Every organ transplant patient in the world faces the potential danger of his/her body rejecting a new organ, such as a heart, kidney or liver. Immunosuppressant drugs are required to help prevent rejection.

2 Apr 2014

UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

UCLA Scientist Dr. Ira Kurtz has received a $3 million gift from the Donald T. Sterling Foundation to fund research on the structural properties of key proteins in the kidney that affect its function in health and disease.

2 Apr 2014

Transplant News and Research

Obeticholic acid meets primary composite endpoint in Phase III study

Oral therapy cures hepatitis C infection in more than 90% of patients with liver cirrhosis

Adoptive T-cell therapy may help in treating liver cancer, says study

New research provides new hope for liver transplant patients with recurring hepatitis C

Study shows impact of hepatic encephalopathy on liver disease patients

Inserm plays key role in developing European research

Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

Gilead Sciences announces positive results from LDV/SOF phase 2 studies on HCV infection

Restoration Robotics presents revolutionary robotic systems at Orlando Live Surgery Workshop

Ambit initiates QUANTUM-R Phase 3 clinical trial of quizartinib in FLT3-ITD positive AML patients

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients

MCVI receives federal approval to launch adult heart transplant program at Memorial Regional Hospital

Transplant drugs may help defeat HIV

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Research findings suggest new strategy in fight against HIV infection

Researcher finds simple blood test that predicts person's risk for sudden cardiac death

AB Sciex launches immunosuppressants kit to improve health care

UCLA scientist wins $3M gift for research on structural properties of key proteins in kidney

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News